Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 45

Results For "low"

3891 News Found

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
R&D | February 04, 2026

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project


Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%
News | February 03, 2026

Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%

Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh


Dr. David Berman to Join Moderna as Chief Development Officer
People | February 02, 2026

Dr. David Berman to Join Moderna as Chief Development Officer

Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics


Hester Biosciences posts strong Q3 profit surge as poultry business powers growth
News | February 02, 2026

Hester Biosciences posts strong Q3 profit surge as poultry business powers growth

The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period


Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
News | February 02, 2026

Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY

Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%


Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal
News | January 31, 2026

AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal

CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform


Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
News | January 30, 2026

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model